Adverum Biotechnologies Inc  

(Public, NASDAQ:ADVM)   Watch this stock  
Find more results for ADVM
2.45
0.00 (0.00%)
Aug 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.40 - 2.50
52 week 2.40 - 4.55
Open 2.45
Vol / Avg. 156,186.00/155,389.00
Mkt cap 106.05M
P/E     -
Div/yield     -
EPS -1.53
Shares 43.29M
Beta 2.44
Inst. own 53%
Nov 6, 2017
Q3 2017 Adverum Biotechnologies Inc Earnings Release (Estimated) Add to calendar
Aug 8, 2017
Q2 2017 Adverum Biotechnologies Inc Earnings Release
Jun 7, 2017
Adverum Biotechnologies Inc at Jefferies Healthcare Conference
May 30, 2017
Adverum Biotechnologies Inc at Boston Biotech Boston CEO Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -2468.68% -7817.66%
Operating margin -2611.88% -7923.30%
EBITD margin - -3640.34%
Return on average assets -21.30% -45.60%
Return on average equity -23.30% -48.59%
Employees 61 -
CDP Score - -

Address

1035 Obrien Dr
MENLO PARK, CA 94025-1408
United States - Map
+1-650-2726269 (Phone)
+1-650-3621908 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company's product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).

Officers and directors

Paul B. Cleveland Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Amber Salzman Ph.D. Chief Executive Officer, Principal Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Steven D. Schwartz M.D. Co-Founder, Independent Director
Age: 55
Bio & Compensation  - Reuters
Leone D. Patterson Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Samuel B. Barone M.D. Senior Vice President, Clinical Development
Age: 44
Bio & Compensation  - Reuters
Athena M. Countouriotis M.D. Senior Vice President, Chief Medical Officer
Age: 45
Bio & Compensation  - Reuters
Mehdi Gasmi Ph.D. Chief Science and Technology Officer
Age: 50
Bio & Compensation  - Reuters
Jennifer C Cheng Vice President, General Counsel
Age: 44
Bio & Compensation  - Reuters
Mitchell H. Finer Ph.D. Director
Age: 58
Bio & Compensation  - Reuters
Patrick Machado J.D. Independent Director
Age: 53
Bio & Compensation  - Reuters